-2.85% for GSK stock as price action stays near daily low

Traders Union
All News
Financial News
GSK drops 2.85% today to GBX1,858.50

Highlights

GSK finalized a $10.6 billion acquisition of Nuvalent, broadening its lung cancer portfolio and strengthening future oncology revenue prospects.
A recent share buyback increased treasury holdings to 6.61% of voting rights, slightly reducing free float and consolidating ownership.
Technical indicators show strong bearish momentum, with GSK trading below key moving averages and a 74% probability of further downside within a GBX1,801.03–1,915.97 range.

Pipeline expansion and buyback reshape outlook but selling persists

GSK has completed a $10.6 billion acquisition of Nuvalent, aiming to expand its lung cancer treatment portfolio and diversify its therapeutic pipeline. The integration of Nuvalent's targeted oncology assets introduces new potential revenue streams and alters GSK's longer-term growth profile. In addition, GSK recently concluded a share buyback programme, repurchasing over 1.6 million ordinary shares and increasing treasury shares to 6.61% of voting rights, which marginally reduces free float and consolidates existing ownership concentration, though price action has remained under broader selling pressure.

Short-term technicals flag strong sell as sellers control momentum

On the hourly chart, GSK is below its MA-20 at GBX1,917.79 and MA-50 at GBX1,883.55, indicating seller momentum in both short and medium-term timeframes. However, the price still sits above the daily MA-200 at GBX1,846.73, offering a measure of long-term support. The Ichimoku Kijun level at GBX1,891.48 serves as immediate resistance, while the session closed with a negative gap of 16.78 and near today's low. MACD remains neutral, but ADX signals a sell, suggesting persistent downward momentum. RSI reads 26.83, with Stoch RSI, CCI, and BBP all showing oversold conditions or a tilt toward sellers. The Awesome Oscillator also indicates a strong sell, and all observed momentum and oscillator measures are aligned to the downside. No notable divergence is present among these indicators.

Further declines favored as support at risk in volatile range

Near term, GSK is likely to trade within a typical volatility band of GBX1,801.03 to GBX1,915.97. There is a 74% probability of further downside outweighing the likelihood of a rebound, which is estimated at 26%. The baseline scenario anticipates continued fluctuations within this range unless a sustained breakout above immediate resistance materializes. A bearish scenario would involve a decisive move below the support band, increasing the risk of further declines.

Anton Kharitonov, expert at Traders Union, sees GSK's completed Nuvalent acquisition as a positive step for long-term growth but notes the market remains unconvinced in the near term. Technical indicators and momentum are strongly negative, with price action under key moving averages despite recent share buybacks. He remains cautious due to persistent selling pressure and oversold conditions. "Unless GSK reclaims short-term resistance at GBX1,891.48, I don’t expect a sustained rebound yet."

Previously it was reported that GSK's ongoing share buyback program and the acquisition of Nuvalent were pivotal steps intended to enhance capital return and long-term growth prospects, despite the persistence of bearish momentum. The current analysis reinforces this outlook by highlighting that downside risks remain elevated, and traders should monitor for any shift in momentum that could trigger a breakout above immediate resistance levels.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.